Near-term catalysts for Timber may come from its late-stage clinical development pipeline, which includes two Phase 2b assets and significant advancement of a preclinical asset towards an IND, all targeting rare dermatologic conditions. Rare dermatology is currently one of the highest growth subsegments within the dermatology market. Looking longer-term, additional value is likely to be generated from each drug's potential to treat multiple indications, bringing an inherent ability to expand into additional dermatology drug markets.
The company is positioned for growth and has already proven that its programs have value. Aside from its
Also, because of the company's focus on developing orphan indications where no FDA approved treatments are available, they are well-positioned to receive a valuable Priority Review Voucher for their TMB-003, which have been valuable for sale on the open market.some .
Clinical Focus On Rare Dermatologic Conditions
An attractive feature about
Notably, these three clinical programs bring the potential for the expansion of each product's treatment indications. These broader treatment opportunities not only lower trial risk but also increase the potential for partnership and licensing agreements with large pharmaceutical companies. However, it's more probable that Timber will see these programs through to eventual marketing, noting that
Additionally, the company's financial health allows for strategic options that can include broadening their clinical focus toward additional dermatological indications. Thus, Timber does control its pipeline destiny.
Approval Pathways From 505(b)(2) Filings
A key advantage to the
Moreover, the 505(b)(2) pathway significantly de-risks the Timber product portfolio by inheriting already established clinical proof-of-concept, proven mechanism of action, and well-known chemistry, manufacturing, and control processes that acknowledge positive safety profiles.
Even as a young public company,
Although shares opened trading under some pressure, it's likely that investors don't understand the strength of either the pipeline or the company's balance sheet.
Media Contact:
ken@soulstringmedia.com
(305)780-6988
Disclaimer
This communication was produced by
PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. For full disclaimers, including compensation received for professional services, please click here.
Media Contact
Company
Contact Person:
Email: info@ceo3in60.com
City:
State:
Country:
Website: https://pcgadvisory.com/
Source: www.abnewswire.com
.
(C) 2020 M2 COMMUNICATIONS, source